Harjes Ulrike, Kalucka Joanna, Carmeliet Peter
Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, Department of Oncology, University of Leuven, Leuven B-3000, Belgium; Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, VIB, Leuven B-3000, Belgium.
Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, Department of Oncology, University of Leuven, Leuven B-3000, Belgium; Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, VIB, Leuven B-3000, Belgium.
Crit Rev Oncol Hematol. 2016 Jan;97:15-21. doi: 10.1016/j.critrevonc.2015.10.011. Epub 2015 Nov 1.
Tumour angiogenesis has long been recognised as a target for anti-cancer therapy. The current approach of inhibiting the VEGF pathway has shown benefit in the clinic, though less than anticipated. We recently documented that glycolytic metabolism in endothelial cells (ECs) fuels angiogenesis, rendering it a possible target for inhibiting vascular growth in pathological conditions. More recently, we reported that the oxidation of fatty acids (FA) is irreplaceable for EC proliferation by providing carbons for de novo nucleotide synthesis. Furthermore, ECs are rather unique in this respect, creating novel therapeutic opportunities. Here, we review and compare the current understanding of FA utilisation in ECs and tumour cells (TCs).
肿瘤血管生成长期以来一直被视为抗癌治疗的靶点。目前抑制血管内皮生长因子（VEGF）途径的方法在临床上已显示出益处，尽管不如预期。我们最近记录到，内皮细胞（ECs）中的糖酵解代谢为血管生成提供能量，使其成为在病理条件下抑制血管生长的一个可能靶点。最近，我们报道脂肪酸（FA）氧化通过为从头合成核苷酸提供碳源，对EC增殖是不可替代的。此外，ECs在这方面相当独特，创造了新的治疗机会。在这里，我们综述并比较了目前对ECs和肿瘤细胞（TCs）中FA利用的理解。
